Moxifloxacin modulates inflammation during murine pneumonia
© Beisswenger et al.; licensee BioMed Central Ltd. 2014
Received: 3 February 2014
Accepted: 10 July 2014
Published: 17 July 2014
Moxifloxacin is a synthetic antibacterial agent belonging to the fluoroquinolone family. The antimicrobial activity of quinolones against Gram-positive and Gram-negative bacteria is based on their ability to inhibit topoisomerases. Quinolones are described to have immunomodulatory features in addition to their antimicrobial activities. It was the goal of this study to examine whether a short term treatment with moxifloxacin modulates the inflammation during a subsequently induced bacterial infection in an animal model.
Mice were treated with moxifloxacin or saline for two consecutive days and were subsequently intranasally infected with viable or heat-inactivated bacterial pathogens (Streptococcus pneumoniae, Pseudomonas aeruginosa) for 6 and 24 hours. Measurements of cytokines in the lungs and plasma were performed. Alveolar cells were determined in bronchoalveolar lavage fluits.
The inflammation was increased after the inoculation of viable bacteria compared to inactivated bacteria. Numbers of total immune cells and neutrophils and concentrations of inflammatory mediators (e.g. KC, IL-1β, IL-17A) were significantly reduced in lungs of moxifloxacin-treated mice infected with inactivated and viable bacterial pathogens as compared to infected control mice. Plasma concentrations of inflammatory mediators were significantly reduced in moxifloxacin-treated mice. Immunohistochemistry showed a stronger infiltrate of TNF-α-expressing cells into lungs of saline-treated mice infected with viable P. aeruginosa as compared to moxifloxacin-treated mice.
These data show that in this pneumonia model moxifloxacin has anti-inflammatory properties beyond its antibacterial activity.
KeywordsMoxifloxacin Pneumonia Infection Inflammation
Respiratory tract diseases, such as pneumonia, cystic fibrosis (CF), and chronic obstructive pulmonary disease (COPD), are worldwide a leading cause of mortality . Acute and chronic inflammations leading to destruction of lung tissue are characteristic hallmarks of these diseases. For example, in severe pneumonia the infecting pathogens and the inflammatory response of the host cause a breach of epithelial and endothelial barriers [2, 3]. As a pathophysiological consequence, bacteria, components of bacteria (e.g. LPS, lipoproteins), and inflammatory mediators translocate from epithelial surfaces into subepithelial compartments and into the bloodstream. In subepithelial compartments, bacteria and components of bacteria are recognized by immune cells. Activated immune cells further contribute to excessive inflammation by releasing inflammatory mediators and directing additional effector cells from the bloodstream into the parenchyma of the lung . Thus, formation of edema and impaired pulmonary gas exchange are a hallmark of severe pneumonia [2, 3]. Acute and chronic inflammation and infection of the lung also contribute to tissue destruction and loss of lung function in COPD and CF [1, 5]. Bacterial and viral infections are associated with exacerbations of COPD [1, 6]. In CF, ongoing inflammation and activation of immune mechanisms is evoked by colonizing bacteria, such as P. aeruginosa.
Moxifloxacin is a synthetic antibacterial agent belonging to the fluoroquinolone family. Moxifloxacin is well established in the treatment of patients suffering from pneumonia  or acute exacerbation of COPD . The minimum inhibitory concentrations (MICs) for moxifloxacin have been shown to be between 0.8 to 2 mg/l for P. aeruginosa (e.g. strain PAO1) and 0.06 to 0.5 mg/l for S. pneumoniae [10–13]. The antimicrobial activities of fluoroquinolones such as moxifloxacin are based on their ability to inhibit topoisomerases (e.g. DNA gyrase and topoisomerase IV). There is strong evidence that fluoroquinolones additionally exhibit immunomodulatory functions during inflammation and microbial infection besides their bactericidal activities . In vitro studies showed that clinically relevant concentrations of moxifloxacin inhibit the synthesis of inflammatory mediators (e.g. IL-1, TNF-α, IL-6, IL-8) in human peripheral blood mononuclear cells and in the monocytic cell line THP-1 stimulated with LPS, LTA, heat-inactivated bacteria, and Aspergillus fumigatus. This is likely due to the inhibition of NF-κB- and MAP kinase-dependent signaling pathways [14–16]. In vitro studies further revealed that moxifloxacin inhibits the activation of MAP kinase and NF-kB signaling cascades, the synthesis of nitric oxide, and the expression of the chemokines IL-6 and IL-8 in human respiratory epithelial cell lines stimulated with inflammatory cytokines [17, 18]. To date, it is not sufficiently understood how fluoroquinolones modulate inflammation and particularly the activation of cellular signaling molecules such as NF-κB- or MAP kinases. However, it has been shown that fluoroquinolones affect phosphodiesterases and intracellular cAMP levels [19, 20]. In addition, it has also been suggested that the immunomodulatory effects of fluoroquinolones are due to the inhibition of topoisomerases, which leads to a stress response in eukaryotic cells [8, 19, 21].
It was the goal of this study to gain insight into the immunomodulatory features of moxifloxacin during murine pneumonia. To study whether moxifloxacin modulates the inflammatory response of the host mice were treated with moxifloxacin before infection of the lung with viable or heat-inactivated bacterial pathogens. Infection with heat-inactivated bacteria allowed examining the effects of moxifloxacin treatment on the inflammatory response of the host without being affected by the impact of moxifloxacin on the viability of the bacteria. To demonstrate whether the immunomodulatory features of moxifloxacin depend on the infecting bacterial species we chose to infect mice with distantly related Gram-negative and Gram-positive bacterial species (S. pneumoniae, P. aeruginosa) which are known to have different susceptibility to moxifloxacin. The results further demonstrate whether a bacterial stimulation using inactivated bacteria differs in comparison to an infection caused by viable bacteria.
P. aeruginosa strain PAO1 was grown overnight at 37°C on LB agar plates. Bacterial cells were taken from the plate, resuspended in LB medium, and incubated for 2-4 hours at 37°C and 150 rpm. A type 6A clinical isolate of S. pneumoniae was cultured as described before . After washing with PBS, bacteria were adjusted to OD600 = 1 and heat-inactivated for 10 min at 95°C or used directly for infection. Mice (C57BL/6N) were maintained under a pathogen-free condition. All animal experiments were approved by the Landesamt für Soziales, Gesundheit und Verbraucherschutz of the State of Saarland following the national guidelines for animal treatment. To examine the effect of moxifloxacin on the inflammatory response of the host during bacterial pneumonia mice were injected i.p. with 100 mg/kg moxifloxacin twice a day for two consecutive days. Control mice received saline. Two hours after the final moxifloxacin injection, moxifloxacin-treated and control animals were infected with bacteria . Mice were slightly anesthetized by i.p. injection of 2.6 mg of ketaminhydrochloride (Ketanest; Pfizer, Germany) and 0.18 mg of xylazinhydrochloride (Rompun; Bayer, Germany) per mouse and infected intranasally with heat-inactivated (low dose: 1 × 106 to 5 × 106 CFU, high dose 1 × 107 to 5 × 107 CFU) and viable (1 × 107 to 5 × 107) P. aeruginosa and with heat-inactivated and viable S. pneumoniae (5 × 106 to 1 × 107) or with PBS alone as control. At least five mice per group were infected with viable or inactivated bacteria or treated with PBS as control. Six or 24 hours after the bacterial infection, mice were euthanized, the tracheae were cannulated and a bronchoalveolar lavage (BAL) was performed with 1 ml of PBS flushed three times into the lungs. Lungs were removed for immunohistochemistry. BAL fluids were centrifuged at 4°C to obtain BAL cells and cell-free supernatants. Alveolar cells were suspended in 1 ml of PBS. Total cell numbers were determined and cytospins were prepared. Macrophages, neutrophils, lymphocytes, and eosinophils were differentiated by light microscopy. Blood was collected by cardiac puncture into EDTA (15 μl, 0.8 M) containing 1 ml syringes and plasma was removed after centrifugation. Plasma and BAL fluids were kept at -80°C until use.
Determination of cytokine concentrations
Concentrations of the inflammatory cytokines KC and IL-1β were assessed by enzyme-linked immunosorbent assay (ELISA) using a Tecan Ultra 384 ELISA reader and the software Magellan (Tecan, Germany). All ELISA kits were purchased from R&D Systems (UK) and used as instructed by the manufacturer. IL-17A and IL-10 were assessed by cytometric bead array (CBA, BD Bioscience, Germany).
RNA isolation and realtime RT-PCR
Total RNA from lungs was isolated using TRIzol reagents (Life Technologies, Germany) according to the manufacturer's manual. 1 μg of total RNA was reversely transcribed to cDNA using the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, Germany) according to the manufacturer's manual. qRT-PCR was performed with a reaction mix including the SensiMix SYBR & Fluorescein Kit (Bioline, Germany), using the iCycler (Bio-Rad Laboratories, Germany) with a 2-step protocol (15 sec at 95°C/45 sec at 60°C). Specificity of amplification was controlled by melt curve analysis and gelelectrophoresis. RT-PCR results were analysed with the ΔΔCT method , using GAPDH as an internal standard to normalize mRNA amounts.
Lungs of mice were embedded in paraffin and immunohistochemistry was performed as described earlier . TNF-α was detected with primary antibodies (Abcam, UK) diluted 1:100 in TBS (Tris-buffered saline). A biotinylated anti-rabbit secondary antibody was added (DAKO, Denmark), followed by avidin-horseradish peroxidase reagent (EnVision System (AEC), DAKO, Denmark). Imaging was performed using the software Cell Sense Dimension (Olympus, Germany). TNF-α staining was quantified (% area) using ImageJ software.
Values are displayed as mean ± SEM. Comparisons between groups were analyzed by ANOVA (Newman-Keuls multiple comparison test). Results were considered statistically significant for p < 0.05. All statistical tests were performed using the software Prism (GraphPad Software, San Diego, CA, USA).
Moxifloxacin treatment affects the influx of immune cells into lungs during bacterial pneumonia
Moxifloxacin treatment resulted in an increased clearance of P. aeruginosa and S. pneumoniae in the lungs of mice infected with viable bacteria indicating a bactericidal activity of moxifloxacin in our pneumonia model against both bacterial species. No viable bacteria were detected in BAL fluids of moxifloxacin-treated mice infected with 5 × 106 CFU of S. pneumoniae 24 hours post infection, whereas 7 × 103 (±3 × 103) CFU of viable S. pneumoniae were determined in BAL fluids of saline-treated control mice. In mice infected with 107 CFU of P. aeruginosa for 6 hours, 4 × 105 (±2 × 105) CFU were detected in BAL fluids of saline-treated control mice and 9 × 102 (±1.3 × 103) CFU in BAL fluids of moxifloxacin-treated mice.
These data suggest that moxifloxacin attenuates the inflammatory response in the lung during murine pneumonia partly independent of its bactericidal activity.
Expression of inflammatory cytokines in lungs of moxifloxacin-treated mice
Concentrations of KC in blood of mice treated with moxifloxacin
This study focused on the immunomodulatory functions of the fluoroquinolone moxifloxacin. The principle finding is that moxifloxacin attenuates local and systemic inflammation during bacterial pneumonia in mice and that the anti-inflammatory properties of moxifloxacin depend on both its bactericidal and non-bactericidal activities.
Moxifloxacin is well established in the clinical treatment of patients suffering from community-acquired pneumonia  and acute exacerbation of COPD . In addition, an immunomodulatory effect of moxifloxacin is assumed in clinical situations . Kazama and colleagues, for instance, reported an interesting case of a woman with a dual lung infection caused by Mycoplasma pneumoniae and Bordetella pertussis. The clinical course was unaffected during a therapy with three different antibiotics in series. Only the subsequent treatment with moxifloxacin led to a dramatic clinical improvement and the disappearance of the migratory pulmonary infiltrates. The authors postulated a immunomodulatory role of moxifloxacin suppressing the lymphocyte activity . Furthermore, several in vitro studies showed that moxifloxacin attenuates the inflammatory response in diverse cell types (e.g. monocytes, respiratory epithelial cells) induced by microbial stimuli and inflammatory mediators by inhibiting the activation of MAP kinases and NF-kB [14–18, 28]. Moxifloxacin reduced the cytokine-induced activation of the transcription factor NF-κB and MAP kinases and the synthesis of nitric oxide in the alveolar epithelial cell line A549  and the TNF-α-induced NF-κB- and MAP-kinase-dependent expression of inflammatory mediators (IL-6, IL-8) in cystic fibrosis epithelial cells . Moxifloxacin also inhibited the activation of MAP kinases and NF-κB and the release of inflammatory mediators in human monocytes in response to bacterial stimuli [14–16].
To study whether moxifloxacin reduces the inflammatory response of the host to microbial pathogens as seen in the in vitro studies mentioned above we treated mice with moxifloxacin prior to infection with viable or heat-inactivated bacterial pathogens. In line with the in vitro studies, our murine pneumonia model showed that systemic treatment with moxifloxacin results in an attenuated inflammatory response with reduced levels of pro-inflammatory mediators and neutrophils in the lungs of mice infected with viable and heat-inactivated S. pneumoniae and P. aeruginosa. Even though the inflammation was more accentuated after the inoculation of viable bacteria than of inactivated bacteria and moxifloxacin was more efficient in suppressing the strong inflammation induced by viable bacteria, infection with inactivated bacteria demonstrated that the anti-inflammatory properties of moxifloxacin partly depend on its non-bactericidal activities. A protective function of moxifloxacin apart from its bactericidal activity could also be determined in a murine pneumonia model with Candida albicans in which treatment with moxifloxacin resulted in reduced levels of inflammatory mediators in the lung during the course of infection . In that report, the beneficial reduction of inflammation in the Candida-albicans-induced pneumonia model could not be explained by an antifungal effect of moxifloxacin. This further supports an anti-inflammatory potency of moxifloxacin completely separate from its antimicrobial effect. As moxifloxacin modulated the inflammatory response to distantly related Gram-negative and Gram-positive bacteria with different susceptibility to moxifloxacin and to fungal species, treatment with moxifloxacin may be beneficial for patients with infection-related lung diseases by reducing the inflammatory burden of the lung independent of the infecting pathogen and its susceptibility to the drug.
It is difficult to deduce the specific cell types affected by moxifloxacin from this in vivo study. It seems to be reasonable that moxifloxacin directly effects the activation of immune cells (e.g. alveolar macrophages) by bacterial pathogens in the infected lungs as observed in the mentioned in vitro studies, since IL-17A is expressed by immune cells and not by epithelial cells  and macrophages are a main source of IL-1β during acute infection of the lung . The finding that treatment with moxifloxacin resulted in reduced IL-1β protein concentrations but in increased mRNA transcription in the lungs of mice infected with viable bacteria whereas KC transcription and protein concentrations were reduced in lungs of moxifloxacin-treated mice suggests that moxifloxacin modulates inflammation at different levels. Additional studies are needed to examine whether moxifloxacin-treatment modulates activation of the inflammasome that mediates the activation and release of IL-1β and whether moxifloxacin-treatment differentially affects signaling pathways required for mRNA-transcription and stabilization of specific cytokins. Furthermore, the activation of respiratory epithelial cells also may be modulated by moxifloxacin as epithelial cells are a source of KC during bacterial pneumonia .
Moreover, viability of the bacterial pathogens per se also affected the inflammatory response of the host. Infection with viable bacteria resulted in absolute levels of pro-inflammatory mediators in the lungs and in plasma of mice that were approximately one magnitude higher as compared to infection with heat-inactivated bacteria, even though infection with heat-inactivated P. aeruginosa resulted in a robust influx of total immune cells and neutrophils into the lungs. In addition, moxifloxacin impacted viability of P. aeruginosa and S. pneumoniae. Fewer bacteria could be cultured from lungs of mice treated with moxifloxacin and infected with viable bacteria as compared to lungs of mice treated with saline. The bactericidal activity of moxifloxacin correlated with the inflammatory response of the host since treatment with moxifloxacin, as compared to saline, resulted in reduced levels of inflammatory mediators in lungs and in plasma of mice infected with viable P. aeruginosa and S. pneumoniae and in a reduced influx of immune cells into lungs of mice infected with S. pneumoniae. These results indicate that the viability of bacteria determines the inflammatory response of the host and are in line with a study of Sander et al.  showing that the immune system can distinguish viable from dead microorganisms by sensing prokaryotic viability-associated patterns resulting in differential release of inflammatory mediators via activation of the inflammasome, such as IL-1β. In line with this study, we found that viability of bacteria does not affect the expression of IL-1β at a transcriptional level. However, inactivation of bacteria resulted in significantly reduced protein levels of IL-β in lungs of infected mice. Thus, moxifloxacin seems to modulate inflammation during bacterial pneumonia by reducing the amount of viability-associated patterns and via mechanisms independent of its bactericidal activity.
In conclusion, we show that moxifloxacin reduces the “hyper-inflammation” during murine pneumonia. Pretreatment with moxifloxacin attenuates local and systemic inflammation during bacterial pneumonia in mice. The non-bactericidal properties may be beneficial for patients with infection-related lung diseases.
This study was supported by a grant by Bayer Vital GmbH, Leverkusen, Germany. We thank Sandra Semar for help with histological evaluation.
- Sethi S: Infection as a comorbidity of COPD. Eur Respir J. 2010, 35: 1209-1215. 10.1183/09031936.00081409.PubMedView ArticleGoogle Scholar
- Witzenrath MB, Gutbier AC, Hocke B, Schmeck S, Hippenstiel K, Berger TJ, Mitchell JR, DeLos Toyos S, Rosseau N, Suttorp H, Schutte : Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia. Crit Care Med. 2006, 34: 1947-1954. 10.1097/01.CCM.0000220496.48295.A9.PubMedView ArticleGoogle Scholar
- Matthay MA, Ware LB, Zimmerman GA: The acute respiratory distress syndrome. J Clin Invest. 2012, 122: 2731-2740. 10.1172/JCI60331.PubMedPubMed CentralView ArticleGoogle Scholar
- Shaykhiev R, Bals R: Interactions between epithelial cells and leukocytes in immunity and tissue homeostasis. J Leukoc Biol. 2007, 82: 1-15. 10.1189/jlb.0207096.PubMedView ArticleGoogle Scholar
- Bals R, Weiner DJ, Wilson JM: The innate immune system in cystic fibrosis lung disease. J Clin Invest. 1999, 103: 303-307. 10.1172/JCI6277.PubMedPubMed CentralView ArticleGoogle Scholar
- Sethi S, Murphy TF: Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008, 359: 2355-2365. 10.1056/NEJMra0800353.PubMedView ArticleGoogle Scholar
- Dubin PJ, Martz A, Eisenstatt JR, Fox MD, Logar A, Kolls JK: Interleukin-23-mediated inflammation in Pseudomonas aeruginosa pulmonary infection. Infect Immun. 2012, 80: 398-409. 10.1128/IAI.05821-11.PubMedPubMed CentralView ArticleGoogle Scholar
- Dalhoff A: Immunomodulatory activities of fluoroquinolones. Infection. 2005, 33 (Suppl 2): 55-70.PubMedView ArticleGoogle Scholar
- Wilson R, Anzueto A, Miravitlles M, Arvis P, Alder J, Haverstock D, Trajanovic M, Sethi S: Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J. 2012, 40: 17-27. 10.1183/09031936.00090311.PubMedPubMed CentralView ArticleGoogle Scholar
- Lister PD, Sanders CC: Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. J Antimicrob Chemother. 2001, 47: 811-818. 10.1093/jac/47.6.811.PubMedView ArticleGoogle Scholar
- Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R: In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother. 1997, 41: 101-106.PubMedPubMed CentralGoogle Scholar
- Zhang L, Li XZ, Poole K: Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia. J Antimicrob Chemother. 2001, 48: 549-552. 10.1093/jac/48.4.549.PubMedView ArticleGoogle Scholar
- Buyck JM, Tulkens PM, Van BF: Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes. Antimicrob Agents Chemother. 2013, 57: 2310-2318. 10.1128/AAC.02609-12.PubMedPubMed CentralView ArticleGoogle Scholar
- Araujo FG, Slifer TL, Remington JS: Effect of moxifloxacin on secretion of cytokines by human monocytes stimulated with lipopolysaccharide. Clin Microbiol Infect. 2002, 8: 26-30. 10.1046/j.1469-0691.2002.00374.x.PubMedView ArticleGoogle Scholar
- Weiss T, Shalit I, Blau H, Werber S, Halperin D, Levitov A, Fabian I: Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kappaB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines. Antimicrob Agents Chemother. 2004, 48: 1974-1982. 10.1128/AAC.48.6.1974-1982.2004.PubMedPubMed CentralView ArticleGoogle Scholar
- Choi JH, Song MJ, Kim SH, Choi SM, Lee DG, Yoo JH, Shin WS: Effect of moxifloxacin on production of proinflammatory cytokines from human peripheral blood mononuclear cells. Antimicrob Agents Chemother. 2003, 47: 3704-3707. 10.1128/AAC.47.12.3704-3707.2003.PubMedPubMed CentralView ArticleGoogle Scholar
- Werber S, Shalit I, Fabian I, Steuer G, Weiss T, Blau H: Moxifloxacin inhibits cytokine-induced MAP kinase and NF-kappaB activation as well as nitric oxide synthesis in a human respiratory epithelial cell line. J Antimicrob Chemother. 2005, 55: 293-300. 10.1093/jac/dkh525.PubMedView ArticleGoogle Scholar
- Blau H, Klein K, Shalit I, Halperin D, Fabian I: Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line. Am J Physiol Lung Cell Mol Physiol. 2007, 292: L343-L352.PubMedView ArticleGoogle Scholar
- Dalhoff A, Shalit I: Immunomodulatory effects of quinolones. Lancet Infect Dis. 2003, 3: 359-371. 10.1016/S1473-3099(03)00658-3.PubMedView ArticleGoogle Scholar
- Bailly S, Fay M, Roche Y, Gougerot-Pocidalo MA: Effects of quinolones on tumor necrosis factor production by human monocytes. Int J Immunopharmacol. 1990, 12: 31-36. 10.1016/0192-0561(90)90065-U.PubMedView ArticleGoogle Scholar
- Riesbeck K, Forsgren A, Henriksson A, Bredberg A: Ciprofloxacin induces an immunomodulatory stress response in human T lymphocytes. Antimicrob Agents Chemother. 1998, 42: 1923-1930.PubMedPubMed CentralGoogle Scholar
- Ratner AJ, Lysenko ES, Paul MN, Weiser JN: Synergistic proinflammatory responses induced by polymicrobial colonization of epithelial surfaces. Proc Natl Acad Sci U S A. 2005, 102: 3429-3434. 10.1073/pnas.0500599102.PubMedPubMed CentralView ArticleGoogle Scholar
- Beisswenger C, Kandler K, Hess C, Garn H, Felgentreff K, Wegmann M, Renz H, Vogelmeier C, Bals R: Allergic airway inflammation inhibits pulmonary antibacterial host defense. J Immunol. 2006, 177: 1833-1837. 10.4049/jimmunol.177.3.1833.PubMedView ArticleGoogle Scholar
- Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29: e45-10.1093/nar/29.9.e45.PubMedPubMed CentralView ArticleGoogle Scholar
- Hess C, Herr C, Beisswenger C, Zakharkina T, Schmid RM, Bals R: Myeloid RelA regulates pulmonary host defense networks. Eur Respir J. 2010, 35: 343-352. 10.1183/09031936.00196408.PubMedView ArticleGoogle Scholar
- Ewig S, Hecker H, Suttorp N, Marre R, Welte T: Moxifloxacin monotherapy versus ss-lactam mono- or combination therapy in hospitalized patients with community-acquired pneumonia. J Infect. 2011, 62: 218-225. 10.1016/j.jinf.2011.01.009.PubMedView ArticleGoogle Scholar
- Kazama I, Tamada T, Nakajima T: Resolution of migratory pulmonary infiltrates by moxifloxacin in a patient with dual infection of Mycoplasma pneumoniae and Bordetella pertussis. Infez Med. 2012, 20: 288-292.PubMedGoogle Scholar
- Shalit I, Horev-Azaria L, Fabian I, Blau H, Kariv N, Shechtman I, Alteraz H, Kletter Y: Immunomodulatory and protective effects of moxifloxacin against Candida albicans-induced bronchopneumonia in mice injected with cyclophosphamide. Antimicrob Agents Chemother. 2002, 46: 2442-2449. 10.1128/AAC.46.8.2442-2449.2002.PubMedPubMed CentralView ArticleGoogle Scholar
- Pfeifer P, Voss M, Wonnenberg B, Hellberg J, Seiler F, Lepper PM, Bischoff M, Langer F, Schafers HJ, Menger MD, Bals R, Beisswenger C: IL-17C is a mediator of respiratory epithelial innate immune response. Am J Respir Cell Mol Biol. 2013, 48: 415-421. 10.1165/rcmb.2012-0232OC.PubMedView ArticleGoogle Scholar
- Sander LE, Davis MJ, Boekschoten MV, Amsen D, Dascher CC, Ryffel B, Swanson JA, Muller M, Blander JM: Detection of prokaryotic mRNA signifies microbial viability and promotes immunity. Nature. 2011, 474: 385-389. 10.1038/nature10072.PubMedPubMed CentralView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.